Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
Recruiting
Phase 4
Interventional Study
Cardiovascular Disease
Dementia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 65 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 162,000 (estimated)
- Sponsor
- Tor Biering-Sørensen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults. Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes more common with increasing age. Some observational studies have suggested that vaccination against herpes zoster may also lower th…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age 65 years and above at the time of consent
2. Self-reported ability to understand written and spoken Danish or English
3. Informed consent form has been signed and dated
Exclusion Criteria:
The study has the following exclusion criteria which will be assessed through sel…
Contacts